(Q39066434)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Anna M. Blom

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Ingrid Eriksson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Anders Österborg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

1 reference

7 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-013-0759-5

29 February 2020

exact match

0 references

cites work

Complement: coming full circle.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Identification of tumor antigens and T-cell epitopes, and its clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Membrane alterations in cancer cells: the role of oxy radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Complement resistance of tumor cells: basal and induced mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Molecular mechanisms of the antitumor effects of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Functional analyses of complement convertases using C3 and C5-depleted sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0759-5

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24198205

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24198205

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-013-0759-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24198205%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference